Zivo Bioscience Inc
ZIVO
Get informed when a big investor buys or sells
+ FollowMarket Cap$14.35M
Close$
$-0.56
113.1% downside
Current Fair Value
113.1% downsideOvervalued by 113.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $14.35 Million |
|---|---|
| Enterprise Value | $14.92 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-2.59 |
| Beta | 0.09 |
| Outstanding Shares | 3,884,517 |
Return
| Return on Equity | 263.93% |
|---|---|
| Return on Assets | -1490.71% |
| Return on Invested Capital | 277.98% |
Valuation & Multiples
| P/E Ratio | -1.45 |
|---|---|
| PEG | -1.65 |
| Price to Sales | - |
| Price to Book Ratio | -4.3 |
| Enterprise Value to Revenue | 125.34 |
| Enterprise Value to EBIT | -1.51 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.04 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
June 3, 2026
EPS Estimate
$-0.30
Average shareholder expectationRevenue Estimate
$125,000
Average shareholder expectationNext Earnings Call
Expected Date
September 2, 2026
EPS Estimate
$-0.28
Average shareholder expectationRevenue Estimate
$202,000
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Zivo Bioscience Inc
8 employees
CEO: Andrew Dahl